White Matter Abnormalities Track Disease Progression in Multiple System Atrophy
Movement Disorders Clinical Practice · 2024
DOI: 10.1002/mdc3.14147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, 2024. Verfasst von Sheelakumari Raghavan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Multiple System Atrophy, Disease Progression, White Matter, Magnetic Resonance Imaging. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institutes of Health, USA, FDA HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Background
White matter (WM) abnormalities have been implicated in clinically relevant functional decline in multiple system atrophy (MSA).
Objective
To identify the WM and gray matter (GM) abnormalities in MSA and assess the utility of longitudinal structural and diffusion changes as surrogate markers for tracking disease progression in MSA.
Methods
Twenty‐seven participants with early MSA [15 with clinically predominant cerebellar (MSA‐C) and 12 with clinically predominant parkinsonian features (MSA‐P)] and 14 controls were enrolled as a part of our prospective, longitudinal study of synucleinopathies. Using structural magnetic resonance imaging (MRI) and diffusion MRI (diffusion tensor and neurite orientation and dispersion density imaging), we analyzed whole and regional brain changes in these participants. We also evaluated temporal imaging trajectories based on up to three annual follow‐up scans and assessed the impact of baseline diagnosis on these imaging biomarkers using mixed‐effect models.
Results
MSA patients exhibited more widespread WM changes than GM, particularly in the cerebellum and brainstem, with greater severity in MSA‐C. Structural and diffusion measures in the cerebellum WM and brainstem deteriorated with disease progression. Rates of progression of these abnormalities were similar in both MSA subtypes, reflecting increasing overlap of clinical features over time.
Conclusion
WM abnormalities are core features of MSA disease progression and advance at similar rates in clinical MSA subtypes. Multimodal MRI imaging reveals novel insights into the distribution and pattern of brain abnormalities and their progression in MSA. Selected structural and diffusion measures may be useful for tracking disease progression in MSA clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Mayo Clinic, Rochester, MN, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
- Department of Information Technology, Mayo Clinic, Rochester, MN, USA.
- Department of Neurology, Mayo Clinic, Rochester, MN, USA.
ORCID-Profile: Wolfgang Singer, Prashanthi Vemuri
Förderung
- National Institutes of Health, USA
- FDA HHS
- NINDS NIH HHS
- NCATS NIH HHS
- NIA NIH HHS
- National Institutes of Health
- Food and Drug Administration
Zitieren
APA
Raghavan, S., Lesnick, T. G., Castillo, A. M., Reid, R. I., Fought, A. J., Thostenson, K. B., Johnson Sparrman, K. L., Gehrking, T. L., Gehrking, J. A., Sletten, D. M., Low, P. A., Singer, W., & Vemuri, P. (2024). White Matter Abnormalities Track Disease Progression in Multiple System Atrophy. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.14147
Vancouver
Raghavan S, Lesnick TG, Castillo AM, Reid RI, Fought AJ, Thostenson KB, et al. White Matter Abnormalities Track Disease Progression in Multiple System Atrophy. Movement Disorders Clinical Practice. 2024. doi:10.1002/mdc3.14147
BibTeX
@article{Raghavan2024,
author = {Raghavan, Sheelakumari and Lesnick, Timothy G and Castillo, Anna M and Reid, Robert I and Fought, Angela J and Thostenson, Kaely B and Johnson Sparrman, Kohl L and Gehrking, Tonette L and Gehrking, Jade A and Sletten, David M and Low, Phillip A and Singer, Wolfgang and Vemuri, Prashanthi},
title = {White Matter Abnormalities Track Disease Progression in Multiple System Atrophy},
journal = {Movement Disorders Clinical Practice},
year = {2024},
doi = {10.1002/mdc3.14147}
}
EUVIMED